Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells $10,308.06 in Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff sold 12,726 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the transaction, the chief executive officer now owns 192,039 shares of the company’s stock, valued at $155,551.59. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $0.83 on Thursday. Seres Therapeutics, Inc. has a 52 week low of $0.54 and a 52 week high of $1.53. The company’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $0.85. The company has a market capitalization of $141.68 million, a P/E ratio of -3.61 and a beta of 2.11.

Analysts Set New Price Targets

MCRB has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Chardan Capital reiterated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Seres Therapeutics presently has an average rating of “Hold” and a consensus target price of $5.08.

Institutional Investors Weigh In On Seres Therapeutics

Large investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new position in Seres Therapeutics in the 3rd quarter worth $374,000. Charles Schwab Investment Management Inc. boosted its position in shares of Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company’s stock worth $708,000 after buying an additional 222,771 shares during the period. FMR LLC grew its holdings in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock worth $21,625,000 after buying an additional 140,096 shares in the last quarter. Providence Wealth Advisors LLC grew its holdings in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock worth $93,000 after buying an additional 22,250 shares in the last quarter. Finally, State Street Corp raised its position in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 43,700 shares during the last quarter. Institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.